CN102327288B - 一种注射用血小板冻干粉制剂及其制备方法 - Google Patents
一种注射用血小板冻干粉制剂及其制备方法 Download PDFInfo
- Publication number
- CN102327288B CN102327288B CN2011103123758A CN201110312375A CN102327288B CN 102327288 B CN102327288 B CN 102327288B CN 2011103123758 A CN2011103123758 A CN 2011103123758A CN 201110312375 A CN201110312375 A CN 201110312375A CN 102327288 B CN102327288 B CN 102327288B
- Authority
- CN
- China
- Prior art keywords
- platelet
- injection
- cell
- freeze
- hours
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 48
- 238000002347 injection Methods 0.000 title claims abstract description 44
- 239000007924 injection Substances 0.000 title claims abstract description 44
- 239000000843 powder Substances 0.000 title claims abstract description 24
- 210000001772 blood platelet Anatomy 0.000 title abstract description 173
- OTPDWCMLUKMQNO-UHFFFAOYSA-N 1,2,3,4-tetrahydropyrimidine Chemical compound C1NCC=CN1 OTPDWCMLUKMQNO-UHFFFAOYSA-N 0.000 claims abstract description 35
- 238000007710 freezing Methods 0.000 claims abstract description 22
- 230000008014 freezing Effects 0.000 claims abstract description 22
- BVWAOXGNDVRQSO-UHFFFAOYSA-N 3-hydroxy-2,6-dihydro-1h-pyrimidine Chemical compound ON1CNCC=C1 BVWAOXGNDVRQSO-UHFFFAOYSA-N 0.000 claims abstract description 19
- 238000001035 drying Methods 0.000 claims description 36
- 238000010792 warming Methods 0.000 claims description 36
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 21
- 239000000243 solution Substances 0.000 claims description 20
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 19
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 19
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 19
- 238000005406 washing Methods 0.000 claims description 19
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 18
- JGSARLDLIJGVTE-UHFFFAOYSA-N 3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-UHFFFAOYSA-N 0.000 claims description 18
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 18
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 18
- 239000002577 cryoprotective agent Substances 0.000 claims description 18
- 238000012856 packing Methods 0.000 claims description 18
- 239000008227 sterile water for injection Substances 0.000 claims description 18
- 230000001954 sterilising effect Effects 0.000 claims description 18
- 238000004659 sterilization and disinfection Methods 0.000 claims description 18
- 239000000725 suspension Substances 0.000 claims description 18
- 229920001503 Glucan Polymers 0.000 claims description 5
- TWNIBLMWSKIRAT-VFUOTHLCSA-N levoglucosan Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@H]2CO[C@@H]1O2 TWNIBLMWSKIRAT-VFUOTHLCSA-N 0.000 claims description 5
- 102000008100 Human Serum Albumin Human genes 0.000 claims 1
- 108091006905 Human Serum Albumin Proteins 0.000 claims 1
- 239000003223 protective agent Substances 0.000 abstract 3
- 239000008176 lyophilized powder Substances 0.000 description 31
- 210000004027 cell Anatomy 0.000 description 20
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 16
- 238000000034 method Methods 0.000 description 10
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 9
- 229940098773 bovine serum albumin Drugs 0.000 description 9
- 230000004913 activation Effects 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 230000036755 cellular response Effects 0.000 description 5
- 230000015271 coagulation Effects 0.000 description 5
- 238000005345 coagulation Methods 0.000 description 5
- 239000013078 crystal Substances 0.000 description 5
- 229960004397 cyclophosphamide Drugs 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 4
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000010253 intravenous injection Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 210000003462 vein Anatomy 0.000 description 4
- GTPQXTSQORFWTG-UHFFFAOYSA-N 1,2,3,4-tetrahydropyrimidine-4-carboxylic acid Chemical compound OC(=O)C1NCNC=C1 GTPQXTSQORFWTG-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 2
- XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 description 2
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241001597008 Nomeidae Species 0.000 description 2
- 229960005305 adenosine Drugs 0.000 description 2
- XSDQTOBWRPYKKA-UHFFFAOYSA-N amiloride Chemical compound NC(=N)NC(=O)C1=NC(Cl)=C(N)N=C1N XSDQTOBWRPYKKA-UHFFFAOYSA-N 0.000 description 2
- 229960002576 amiloride Drugs 0.000 description 2
- XEYBHCRIKKKOSS-UHFFFAOYSA-N disodium;azanylidyneoxidanium;iron(2+);pentacyanide Chemical compound [Na+].[Na+].[Fe+2].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].[O+]#N XEYBHCRIKKKOSS-UHFFFAOYSA-N 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- 229940083618 sodium nitroprusside Drugs 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- 108010001394 Disaccharidases Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010060891 General symptom Diseases 0.000 description 1
- RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Chemical compound CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 108010081391 Ristocetin Proteins 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- BGTFCAQCKWKTRL-YDEUACAXSA-N chembl1095986 Chemical compound C1[C@@H](N)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]([C@H]1C(N[C@H](C2=CC(O)=CC(O[C@@H]3[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)=C2C=2C(O)=CC=C(C=2)[C@@H](NC(=O)[C@@H]2NC(=O)[C@@H]3C=4C=C(C(=C(O)C=4)C)OC=4C(O)=CC=C(C=4)[C@@H](N)C(=O)N[C@@H](C(=O)N3)[C@H](O)C=3C=CC(O4)=CC=3)C(=O)N1)C(O)=O)=O)C(C=C1)=CC=C1OC1=C(O[C@@H]3[C@H]([C@H](O)[C@@H](O)[C@H](CO[C@@H]5[C@H]([C@@H](O)[C@H](O)[C@@H](C)O5)O)O3)O[C@@H]3[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O[C@@H]3[C@H]([C@H](O)[C@@H](CO)O3)O)C4=CC2=C1 BGTFCAQCKWKTRL-YDEUACAXSA-N 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000009514 concussion Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000010118 platelet activation Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 description 1
- 239000011241 protective layer Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 210000001792 thromboblast Anatomy 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
Abstract
Description
组别 | 最大凝集率(%) |
新鲜血小板 | 97.2±5.9 |
实施例1冻干血小板复水后 | 91.6±9.5 |
实施例2冻干血小板复水后 | 91.0±3.7 |
实施例3冻干血小板复水后 | 78.4±4.1 |
实施例4冻干血小板复水后 | 81.9±2.4 |
实施例5冻干血小板复水后 | 77.8±1.2 |
实施例6冻干血小板复水后 | 80.1±6.4 |
实施例7冻干血小板复水后 | 84.0±1.7 |
实施例8冻干血小板复水后 | 79.6±8.3 |
实施例9冻干血小板复水后 | 93.7±5.8 |
实施例10冻干血小板复水后 | 77.9±2.9 |
实施例11冻干血小板复水后 | 90.6±3.4 |
实施例12冻干血小板复水后 | 82.2±4.0 |
实施例13冻干血小板复水后 | 75.3±8.1 |
实施例14冻干血小板复水后 | 69.5±2.2 |
实施例15冻干血小板复水后 | 76.4±9.2 |
实施例16冻干血小板复水后 | 84.1±0.9 |
组别 | 血小板计数 | 最大凝集率(%) |
新鲜血小板 | 4.93 | 100.0±2.9 |
实施例1冻干血小板复水后 | 4.85 | 94.1±1.4 |
实施例2冻干血小板复水后 | 4.70 | 94.7±5.7 |
实施例3冻干血小板复水后 | 3.61 | 82.3±9.5 |
实施例4冻干血小板复水后 | 3.78 | 79.0±6.4 |
实施例5冻干血小板复水后 | 3.22 | 82.8±7.9 |
实施例6冻干血小板复水后 | 3.43 | 85.1±2.1 |
实施例7冻干血小板复水后 | 3.94 | 81.7±8.2 |
实施例8冻干血小板复水后 | 3.29 | 76.4±5.7 |
实施例9冻干血小板复水后 | 4.57 | 92.9±3.0 |
实施例10冻干血小板复水后 | 3.74 | 79.0±8.4 |
实施例11冻干血小板复水后 | 4.83 | 96.1±2.9 |
实施例12冻干血小板复水后 | 3.79 | 80.5±9.1 |
实施例13冻干血小板复水后 | 4.08 | 79.4±6.8 |
实施例14冻干血小板复水后 | 3.62 | 79.8±1.6 |
实施例15冻干血小板复水后 | 4.15 | 75.7±4.4 |
实施例16冻干血小板复水后 | 4.20 | 82.6±7.2 |
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2011103123758A CN102327288B (zh) | 2011-10-17 | 2011-10-17 | 一种注射用血小板冻干粉制剂及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2011103123758A CN102327288B (zh) | 2011-10-17 | 2011-10-17 | 一种注射用血小板冻干粉制剂及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102327288A CN102327288A (zh) | 2012-01-25 |
CN102327288B true CN102327288B (zh) | 2012-11-14 |
Family
ID=45479419
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2011103123758A Active CN102327288B (zh) | 2011-10-17 | 2011-10-17 | 一种注射用血小板冻干粉制剂及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102327288B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11815311B2 (en) | 2019-03-14 | 2023-11-14 | Terumo Bct Biotechnologies, Llc | Lyophilization container fill fixture, system and method of use |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104906052B (zh) * | 2014-03-14 | 2017-09-05 | 复旦大学附属中山医院 | 一种自体来源富血小板血浆冻干粉的制备方法 |
EP3694322A1 (en) | 2017-10-09 | 2020-08-19 | Terumo BCT Biotechnologies, LLC | Lyophilization container and method of using same |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE230923T1 (de) * | 1997-02-07 | 2003-02-15 | Elan Drug Delivery Ltd | Verfahren und zusammensetzungen zur herstellung getrockneter, lagerungsstabiler blutplättchen |
DE602005019064D1 (de) * | 2004-08-12 | 2010-03-11 | Cellphire Inc | Verfahren zur herstellung gefriergetrockneter blutplättchen, gefriergetrocknete blutplättchen enthaltende zusammensetzungen und verwendungsverfahren |
CN101167745B (zh) * | 2007-11-02 | 2010-06-02 | 中国人民解放军军事医学科学院野战输血研究所 | 一种用于血小板冰冻干燥保存的小分子糖稳定缓冲液 |
-
2011
- 2011-10-17 CN CN2011103123758A patent/CN102327288B/zh active Active
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11815311B2 (en) | 2019-03-14 | 2023-11-14 | Terumo Bct Biotechnologies, Llc | Lyophilization container fill fixture, system and method of use |
Also Published As
Publication number | Publication date |
---|---|
CN102327288A (zh) | 2012-01-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU672775B2 (en) | Method of freezing cells and cell-like materials | |
RU2146088C1 (ru) | Концентрированный раствор для хранения в криогенных условиях (варианты), раствор для хранения в криогенных условиях, способ криогенного хранения клеток (варианты), способ криогенного хранения и регенерации жизнеспособных клеток, способ криогенного хранения, регенерации и терапевтического применения клеток | |
FI78236C (fi) | Foerfarande foer framstaellning av en frystorkad doseringsenhet av cis-platina (ii) diamindiklorid. | |
US5731291A (en) | Partially lyophilized fructose-1,6-diphosphate (FDP) for injection into humans | |
CN102487939B (zh) | 一种间充质干细胞储存液 | |
CN102349500A (zh) | 一种间充质干细胞自体保存液 | |
CN101167745B (zh) | 一种用于血小板冰冻干燥保存的小分子糖稳定缓冲液 | |
CN102669087A (zh) | 一种外周血单个核细胞的冻存液及冻存方法 | |
CN112841174A (zh) | 一种用于人脐带间充质干细胞长期保存的冻存液 | |
ES2762966T3 (es) | Procedimiento de crioconservación de células con objetivo terapéutico | |
CN102327288B (zh) | 一种注射用血小板冻干粉制剂及其制备方法 | |
KR101716215B1 (ko) | 즉시 주입가능한 젬시타빈 용액 | |
CN102327289B (zh) | 一种注射用红细胞冻干粉制剂及其制备方法 | |
EP0590514B1 (en) | Blood preserving composition and method for preserving blood | |
CN104222069A (zh) | 红系祖细胞冻存液及其应用 | |
CN111602648B (zh) | 一种免疫细胞无血清冻存液及冻存方法 | |
CN1835754A (zh) | 稳定的医药用河豚毒素冷冻干燥制剂 | |
JPH02191221A (ja) | イノシトールトリホスフェートを含有する移植に関する障害に対する医薬 | |
CN105532644A (zh) | 淋巴细胞的冻存方法 | |
CN103040855B (zh) | 一种磷酸氟达拉滨的药物组合物及其制备方法 | |
ES2763030T3 (es) | Procedimiento de crioconservación de células con objetivo terapéutico | |
CN101953807A (zh) | 一种注射用吗替麦考酚酯冻干粉针剂及其制备方法 | |
WO2013095965A1 (en) | Stable storage of enveloped viruses in histidine aqueous solution | |
CN103054817A (zh) | 一种单磷酸阿糖腺苷的药物组合物及其制备方法 | |
CN1177905A (zh) | 冷冻保存溶液 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: XU WEIDONG Free format text: FORMER OWNER: JINAN HUANTAI PHARMACEUTICAL TECHNOLOGY CO., LTD. Effective date: 20150416 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20150416 Address after: 250101 Shandong city of Ji'nan province high tech Zone Shun Road No. 750 Patentee after: Xu Weidong Address before: 250101 Shandong city of Ji'nan province high tech Zone Shun Road No. 750 Patentee before: Jinan Huantai Pharmaceutical Technology Co., Ltd. |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20151208 Address after: 250101 Shandong city of Ji'nan province high tech Zone Shun Road No. 750 Patentee after: Jinan Huantai Pharmaceutical Technology Co., Ltd. Address before: 250101 Shandong city of Ji'nan province high tech Zone Shun Road No. 750 Patentee before: Xu Weidong |
|
TR01 | Transfer of patent right |
Effective date of registration: 20200703 Address after: No.3787 wangmugong street, Qingzhou Economic Development Zone, Weifang City, Shandong Province Patentee after: Shandong Yizhou Biotechnology Co., Ltd Address before: 250101 Shandong city of Ji'nan province high tech Zone Shun Road No. 750 Patentee before: JINAN HUANTAI MEDICAL TECHNOLOGY Co.,Ltd. |
|
TR01 | Transfer of patent right |